+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Pre-Sterilized/Ready-to-Use Primary Packaging Market: Focus on Cartridges, Syringes and Vials - Distribution by Type of Packaging System, Packaging Material and Key Geography, Industry Trends and Global Forecast, 2021-2030

  • PDF Icon

    Report

  • 297 Pages
  • April 2021
  • Region: Global
  • Roots Analysis
  • ID: 5359099

Overview

Primary packaging, such as vials, syringes, and cartridges, and their affiliated closures, play a vital role in ensuring the stability, and sterility, and thereby, the overall quality, efficacy and safety of a drug product. Moreover, the packaging bears the product label, which provides information related to the drug and, in certain cases, dosing instructions. Pharmaceutical packaging is typically carried out under controlled conditions; specifically, for therapeutics that are designed for parenteral administration, fill/finish is carried out in sterile and aseptic environments. It is also crucial for innovators (or packaging service providers) to choose the appropriate, high quality primary packaging for their respective products; this is because the packaging material is in direct contact with the drug/therapy. Building and maintaining the necessary expertise and infrastructure to support pharmacological fill/finish is a capital-intensive ordeal. Further, the growing complexity of modern pharmacological interventions, such as monoclonal antibodies, cell and gene therapies (which are typically produced in small batches) and the gradual (but imminent) shift to personalized therapies, has prompted drug developers to look for leaner manufacturing and packaging solutions. In this context, cost optimization is important and one of the available ways to save both time and capital is by bypassing manual processing and sterilization of primary packaging and switching to ready-to-use (RTU) formats. 

Pre-sterilized RTU container-closure systems have gradually become very popular and are widely used in the modern pharmaceutical industry. As indicated earlier, such components significantly simplify the overall fill/finish process, primarily by eliminating the need for several additional steps (such as washing, drying and sterilization), which were previously required to prepare primary containers for filling. In other words, using RTU components helps improve operational efficiencies. Drug product manufacturers and fill/finish service providers claim that these off-the-shelf packing and closure systems, help them to better serve their clients in a timely and regulation-compliant manner. In this context, it is worth highlighting that RTU packaging systems were in high demand during the COVID-19 pandemic, when novel vaccines and experimental therapies needed to be produced and packaged for distribution in large quantities. The surge in demand for appropriate packaging solutions in adequate quantities, is likely to persist, significantly adding to the opportunity for RTU package and affiliated closure developers/suppliers. In future, as drug developers continue to strive to achieve greater flexibilities in their operations, we believe that the RTU packaging components market is likely to witness steady growth over the next decade.

Scope of the Report

The “Pre-Sterilized/Ready-to-Use Primary Packaging: Focus on Cartridges, Syringes and Vials (2nd Edition) - Market Distribution by Type of Packaging System (Vials, Syringes, Cartridges and Closures), Packaging Material (Glass and Plastic) and Key Geography (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa and Rest of the World) – Global Forecast 2021-2030” report features an extensive study of the current market landscape and future potential of ready-to-use primary packaging components, including cartridges, syringes and vials, and their respective closure systems (such as stoppers, needle shields and plungers) over the next decade. The study features an in-depth analysis of the key drivers and trends related to this domain. 

Amongst other elements, the report includes:


  • A detailed assessment of the current market landscape of ready-to-use primary packaging components, featuring information on the type of container (vials, syringes, cartridges and others), type of fabrication material used (glass and plastic), sterilization technique used (ethylene oxide sterilization, steam sterilization, gamma irradiation, electron beam sterilization and dry heat sterilization), volume of container (less than 50 ml, 50 ml to 100 ml and more than 100 ml), compatible drug class (biologics and small molecules) and type of closure (stoppers, plungers, tip caps/needle shields, caps and seals). In addition, the chapter includes details related to ready-to-use packaging system manufacturers, along with information on their respective year of establishment, company size, location of headquarters and key players (in terms of number of offerings).
  • A competitiveness analysis of ready-to-use primary packaging system manufacturers based on various relevant parameters, such as supplier power (based on the experience/expertise of the manufacturer) and key product specifications (type of container, type of fabrication material used, type of closure, sterilization technique used and compatible drug class).
  • Elaborate profiles of prominent players engaged in the development of ready-to-use primary packaging systems. Each profile features a brief overview of the company, details related to its financials (if available), product portfolio, recent developments and an informed future outlook.
  • An analysis of the partnerships that have been inked by stakeholders engaged in this domain, during the period 2015-2021, covering acquisitions, product/technology integration agreements, supply agreements, product/technology licensing agreements, product/technology development agreements, service alliances, distribution agreements and other relevant types of deals.
  • An insightful discussion on the impact of the recent COVID-19 pandemic on the businesses of primary pharmaceutical packaging manufacturers. In addition, we have provided information on the strategic initiatives undertaken by pharmaceutical players to mitigate the challenges affiliated with the current global crisis. 
  • An in-depth analysis to estimate the current and future demand for ready-to-use container-closure systems based on various relevant parameters, such as type of packaging system and type of fabrication material used, across different regions, for the period 2021-2030.
  • An elaborate discussion on the key trends (such as the advent of personalized/targeted therapies, shift towards more flexible packaging, rise of modular manufacturing facilities and advancement in robotic packaging solutions) that are likely to have an impact on the future adoption of ready-to-use packaging systems. It also features a Harvey ball analysis, highlighting the relative effect of each trend on the overall pharmaceutical packaging industry.
  • A case study on the use of robotic machinery in pharmaceutical manufacturing and fill/finish operations, highlighting the advantages of using automation/automated technologies in such processes. Further, it presents the profiles of industry players that provide such equipment for aseptic processing of pharmaceuticals. 

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for RTU primary packaging over the coming decade. Based on several parameters, such as target consumer segments, region specific adoption rates and expected prices of these products, we have provided an informed estimate on the likely evolution of the market over the period 2021-2030. The report provides sales forecasts for the overall RTU primary packaging market, wherein both the current and upcoming opportunity is segmented across [A] type of packaging system (vials, syringes, cartridges and closures), [B] type of fabrication material used (glass and plastic) and [C] key geographies (North America, Europe, Asia Pacific, Middle East and North Africa, Latin America and Rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. 

The report features detailed transcripts of interviews held with the following individuals:


  • Julien Marechal (Business Development and Technology Director, Aseptic Technologies)
  • Malcolm Gilmore (Facilitator, BioPhorum Operations Group)
  • Konstantin Kazarian (Former Project Manager of Business Development, PYRAMID Laboratories)
  • Daxesh Shah (Founder and Managing Director, Sagar Rubber)

Key Questions Answered


  • Who are the prominent players engaged in the global pre-sterilized/ready-to-use primary packaging market?
  • What is the relative competitiveness of different ready-to-use primary packaging system manufacturers?
  • Which partnership models are most commonly adopted by stakeholders engaged in this industry?
  • How is the recent COVID-19 pandemic likely to impact the global ready-to-use primary packaging systems market?
  • What is the current, global demand for ready-to-use containers and closures?
  • What are the major market trends and driving factors that are likely to impact the growth of ready-to-use primary packaging systems market?
  • How is the current and future opportunity likely to be distributed across key market segments?

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Pharmaceutical Packaging
3.2.1. Necessity of Pharmaceutical Packaging
3.2.2. Types of Pharmaceutical Packaging
3.2.3. Limitations of Traditional Primary Packaging
3.2.4. Innovation in Pharmaceutical Packaging
3.3. Ready-to-Use Primary Packaging
3.3.1. Sterilization of Primary Packaging Material
3.3.1.1. Sterilization Techniques
3.3.2. Advantages of Ready-to-Use Primary Packaging
3.3.3. Cost Savings with Ready-To-Use Solutions
3.3.4. Demand for Ready-to-Use Primary Packaging
3.3.5 Concluding Remarks

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Pre-Sterilized/Ready-to-Use Primary Packaging: Overall Market Landscape
4.2.1. Analysis by Type of Primary Packaging System
4.3. Pre-Sterilized/Ready-to-Use Containers
4.3.1. Analysis by Type of Container
4.3.2. Analysis by Type of Fabrication Material Used
4.3.3. Analysis by Type of Container and Type of Fabrication Material Used
4.3.4. Analysis by Sterilization Technique Used
4.3.5. Analysis by Type of Container and Sterilization Technique Used
4.3.6. Analysis by Volume of Container
4.3.7. Analysis by Type of Container and Volume of Container
4.3.8. Analysis by Compatible Drug Class
4.3.9. Analysis by Type of Container and Compatible Drug Class
4.4. Pre-Sterilized/Ready-to-Use Closures
4.4.1. Analysis by Type of Closure
4.4.2. Analysis by Type of Fabrication Material Used
4.4.3. Analysis by Type of Closure and Type of Fabrication Material Used
4.4.4. Analysis by Type of Compatible Container
4.4.5. Analysis by Type of Closure and Type of Compatible Container
4.4.6. Analysis by Sterilization Technique Used
4.4.7. Analysis by Type of Closure and Sterilization Technique Used
4.4.8. Analysis by Compatible Drug Class
4.4.9. Analysis by Type of Closure and Compatible Drug Class
4.5. Pre-Sterilized/Ready-to-Use Container-Closure Systems
4.5.1. Analysis by Type of Container
4.5.2. Analysis by Type of Fabrication Material Used for Container
4.5.3. Analysis by Type of Container and Type of Fabrication Material Used for Container
4.5.4. Analysis by Type of Closure
4.5.5. Analysis by Type of Fabrication Material Used for Closure
4.5.6. Analysis by Type of Closure and Type of Fabrication Material Used for Closure
4.5.7. Analysis by Sterilization Technique Used
4.5.8. Analysis by Volume of Container
4.5.9. Analysis by Compatible Drug Class
4.6. Pre-Sterilized/Ready-to-Use Primary Packaging: List of Manufacturers
4.6.1. Analysis by Year of Establishment
4.6.2. Analysis by Company Size
4.6.3. Analysis by Location of Headquarters
4.6.6. Leading Manufacturers: Analysis by Number of Products

5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Methodology
5.3.1. Company Competitiveness: Small Companies
5.3.2. Company Competitiveness: Mid-Sized Companies
5.3.3. Company Competitiveness: Large Companies

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. AptarGroup
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. AptarGroup: Product Portfolio
6.2.3.1. Ready-to-Use Closures
6.2.4. Recent Developments and Future Outlook
6.3. Datwyler Group
6.3.1. Company Overview
6.3.2. Financial Information
6.3.3. Datwyler Group: Product Portfolio
6.3.3.1. Ready-to-Use Closures
6.3.4. Recent Developments and Future Outlook
6.4. DWK Life Sciences
6.4.1. Company Overview
6.4.2. DWK Life Sciences: Product Portfolio
6.4.2.1. Ready-to-Use Container-Closure Systems
6.4.3. Recent Developments and Future Outlook
6.5. Gerresheimer
6.5.1. Company Overview
6.5.2. Financial Information
6.5.3. Gerresheimer: Product Portfolio
6.5.3.1. Ready-to-Use Containers
6.5.4. Recent Developments and Future Outlook
6.6. Ningbo Zhengli Pharmaceutical Packaging
6.6.1. Company Overview
6.6.2. Ningbo Zhengli Pharmaceutical Packaging: Product Portfolio
6.6.2.1. Ready-to-Use Containers
6.6.3. Recent Developments and Future Outlook
6.7. Nipro
6.7.1. Company Overview
6.7.2. Financial Information
6.7.3. Nipro: Product Portfolio
6.7.3.1. Ready-to-Use Containers
6.7.3.2. Ready-to-Use Closures
6.7.4. Recent Developments and Future Outlook
6.8. SCHOTT
6.8.1. Company Overview
6.8.2. Financial Information
6.8.3. SCHOTT: Product Portfolio
6.8.3.1. Ready-to-Use Containers
6.8.3.2. Ready-to-Use Closures
6.8.4. Recent Developments and Future Outlook
6.9. SGD Pharma
6.9.1. Company Overview
6.9.2. Financial Information
6.9.3. SGD Pharma: Product Portfolio
6.9.3.1. Ready-to-Use Containers
6.9.4. Recent Developments and Future Outlook
6.10. Stevanato Group
6.10.1. Company Overview
6.10.2. Stevanato Group: Product Portfolio
6.10.2.1. Ready-to-Use Containers
6.10.2.2. Ready-to-Use Closures
6.10.2.3. Ready-to-Use Container-Closure Systems
6.10.3. Recent Developments and Future Outlook
6.11. Terumo Medical
6.11.1. Company Overview
6.11.2. Terumo Medical: Product Portfolio
6.11.2.1. Ready-to-Use Containers
6.11.3. Recent Developments and Future Outlook
6.12. Transcoject
6.12.1. Company Overview
6.12.2. Transcoject: Product Portfolio
6.12.2.1. Ready-to-Use Containers
6.12.3. Recent Developments and Future Outlook
6.13. West Pharmaceutical Services
6.13.1. Company Overview
6.13.2. Financial Information
6.13.3. West Pharmaceutical Services: Product Portfolio
6.13.3.1. Ready-to-Use Containers
6.13.3.2. Ready-to-Use Closures
6.13.3.3. Ready-to-Use Container-Closure Systems
6.13.3. Recent Developments and Future Outlook

7. PARTNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
7.2. Partnership Models
7.3. Pre-Sterilized/Ready-to-Use Primary Packaging: List of Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Year and Type of Partnership
7.3.4. Analysis by Type of Primary Packaging System
7.3.5. Analysis by Type of Fabrication Material Used
7.3.6. Analysis by Type of Partner
7.3.7. Most Active Players: Analysis by Number of Partnerships
7.3.8. Geographical Analysis
7.3.8.1. Region-wise Distribution
7.3.8.2. Country-wise Distribution

8. IMPACT OF THE COVID-19 PANDEMIC ON PRE-STERILIZED/READY-TO-USE PRIMARY PACKAGING MARKET
8.1. Chapter Overview
8.2. Impact of COVID-19 Pandemic on Primary Packaging Market
8.2.1. Impact on Future Market Opportunity of Pre-Sterilized/ Ready-to-Use Primary Packaging
8.3. Key Strategies to Mitigate Pandemic-related Challenges
8.4. Current Opinions and Recuperative Initiatives of Key Players
8.4.1. Becton Dickinson
8.4.2. Corning
8.4.3. Datwyler Group
8.4.4. Gerresheimer
8.4.5. SCHOTT
8.4.6. SiO2 Materials Science
8.4.7. Stevanato Group
8.4.8. West Pharmaceutical Services
8.4.9. Other Recent Developments

9. DEMAND ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Global Demand for Pre-Sterilized/Ready-to-Use Primary Packaging System, 2021-2030
9.3.1. Analysis by Type of Pre-Sterilized/Ready-to-Use Primary Packaging System
9.3.1.1. Global Demand for Pre-Sterilized/Ready-to-Use Vials, 2021-2030
9.3.1.2. Global Demand for Pre-Sterilized/Ready-to-Use Syringes, 2021-2030
9.3.1.3. Global Demand for Pre-Sterilized/Ready-to-Use Cartridges, 2021-2030
9.3.1.4. Global Demand for Pre-Sterilized/Ready-to-Use Closures, 2021-2030
9.3.2. Analysis by Type of Fabrication Material Used
9.3.2.1. Global Demand for Pre-Sterilized/Ready-to-Use Glass Containers, 2021-2030
9.3.2.1.1. Global Demand for Pre-Sterilized/Ready-to-Use Glass Vials, 2021-2030
9.3.2.1.2. Global Demand for Pre-Sterilized/Ready-to-Use Glass Syringes, 2021-2030
9.3.2.1.3. Global Demand for Pre-Sterilized/Ready-to-Use Glass Cartridges, 2021-2030
9.3.2.2. Global Demand for Pre-Sterilized/Ready-to-Use Plastic Containers, 2021-2030
9.3.2.2.1. Global Demand for Pre-Sterilized/Ready-to-Use Plastic Vials, 2021-2030
9.3.2.2.2. Global Demand for Pre-Sterilized/Ready-to-Use Plastic Syringes, 2021-2030
9.3.2.2.3. Global Demand for Pre-Sterilized/Ready-to-Use Plastic Cartridges, 2021-2030
9.3.3. Analysis by Geography
9.3.3.1. Demand for Pre-Sterilized/Ready-to-Use Primary Packaging Systems in North America, 2021-2030
9.3.3.1.1. Demand for Pre-Sterilized/Ready-to-Use Vials in North America, 2021-2030
9.3.3.1.2. Demand for Pre-Sterilized/Ready-to-Use Syringes in North America, 2021-2030
9.3.3.1.3. Demand for Pre-Sterilized/Ready-to-Use Cartridges in North America, 2021-2030
9.3.3.1.4. Demand for Pre-Sterilized/Ready-to-Use Closures in North America, 2021-2030
9.3.3.2. Demand for Pre-Sterilized/Ready-to-Use Primary Packaging Systems in Europe, 2021-2030
9.3.3.2.1. Demand for Pre-Sterilized/Ready-to-Use Vials in Europe, 2021-2030
9.3.3.2.2. Demand for Pre-Sterilized/Ready-to-Use Syringes in Europe, 2021-2030
9.3.3.2.3. Demand for Pre-Sterilized/Ready-to-Use Cartridges in Europe, 2021-2030
9.3.3.2.4. Demand for Pre-Sterilized/Ready-to-Use Closures in Europe, 2021-2030
9.3.3.3. Demand for Pre-Sterilized/Ready-to-Use Primary Packaging Systems in Asia Pacific, 2021-2030
9.3.3.3.1. Demand for Pre-Sterilized/Ready-to-Use Vials in Asia Pacific, 2021-2030
9.3.3.3.2. Demand for Pre-Sterilized/Ready-to-Use Syringes in Asia Pacific, 2021-2030
9.3.3.3.3. Demand for Pre-Sterilized/Ready-to-Use Cartridges in Asia Pacific, 2021-2030
9.3.3.3.4. Demand for Pre-Sterilized/Ready-to-Use Closures in Asia Pacific, 2021-2030
9.3.3.4. Demand for Pre-Sterilized/Ready-to-Use Primary Packaging Systems in Middle East and North Africa, 2021-2030
9.3.3.4.1. Demand for Pre-Sterilized/Ready-to-Use Vials in Middle East and North Africa, 2021-2030
9.3.3.4.2. Demand for Pre-Sterilized/Ready-to-Use Syringes in Middle East and North Africa, 2021-2030
9.3.3.4.3. Demand for Pre-Sterilized/Ready-to-Use Cartridges in Middle East and North Africa, 2021-2030
9.3.3.4.4. Demand for Pre-Sterilized/Ready-to-Use Closures in Middle East and North Africa, 2021-2030
9.3.3.5. Demand for Pre-Sterilized/Ready-to-Use Primary Packaging Systems in Latin America, 2021-2030
9.3.3.5.1. Demand for Pre-Sterilized/Ready-to-Use Vials in Latin America, 2021-2030
9.3.3.5.2. Demand for Pre-Sterilized/Ready-to-Use Syringes in Latin America, 2021-2030
9.3.3.5.3. Demand for Pre-Sterilized/Ready-to-Use Cartridges in Latin America, 2021-2030
9.3.3.5.4. Demand for Pre-Sterilized/Ready-to-Use Closures in Latin America, 2021-2030
9.3.3.6. Demand for Pre-Sterilized/Ready-to-Use Primary Packaging Systems in Rest of the World, 2021-2030
9.3.3.6.1. Demand for Pre-Sterilized/Ready-to-Use Vials in Rest of the World, 2021-2030
9.3.3.6.2. Demand for Pre-Sterilized/Ready-to-Use Syringes in Rest of the World, 2021-2030
9.3.3.6.3. Demand for Pre-Sterilized/Ready-to-Use Cartridges in Rest of the World, 2021-2030
9.3.3.6.4. Demand for Pre-Sterilized/Ready-to-Use Closures in Rest of the World, 2021-2030
9.4. Concluding Remarks

10. UPCOMING TRENDS IN PHARMACEUTICAL PACKAGING
10.1. Chapter Overview
10.2. Shift to Self-Medication Options using Modern Drug Delivery Devices
10.3. Development of Improved Packaging Components and Efforts to Optimize Manufacturing Costs
10.4. Availability of Modular Facilities
10.5. Growing Demand and Preference for Personalized Therapies
10.6. Rise in Provisions for Automating Fill/Finish Operations
10.7. Surge in Partnership Activity
10.8. Increase in Initiatives Undertaken by Industry Stakeholders in Developing Regions
10.9. Concluding Remarks

11. CASE STUDY: ROBOTS IN PHARMACEUTICAL PACKAGING
11.1. Chapter Overview
11.2. Role of Robots in the Pharmaceutical Industry
11.2.1. Key Considerations for Selecting a Robotic System
11.2.2. Advantages of Robotic Systems
11.2.3. Disadvantages of Robotic Systems
11.3. Companies Providing Robots for Use in the Pharmaceutical Industry
11.4. Companies Providing Equipment Integrated with Robotic Systems for Pharmaceutical Packaging
11.4.1. Aseptic Technologies
11.4.2. AST
11.4.3. Bosch Packaging Technology
11.4.4. Dara Pharmaceutical Packaging
11.4.5. Fedegari Group
11.4.6. IMA
11.4.7. Steriline
11.4.8. Vanrx Pharmasystems

12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Global Pre-Sterilized/Ready-to-Use Primary Packaging Market, 2021-2030
12.3.1. Pre-Sterilized/Ready-to-Use Primary Packaging Market, 2021-2030: Distribution by Type of Primary Packaging System
12.3.1.1. Pre-Sterilized/Ready-to-Use Vials Market, 2021-2030
12.3.1.2. Pre-Sterilized/Ready-to-Use Syringes Market, 2021-2030
12.3.1.3. Pre-Sterilized/Ready-to-Use Cartridges Market, 2021-2030
12.3.1.4. Pre-Sterilized/Ready-to-Use Closures Market, 2021-203
12.3.2. Pre-Sterilized/Ready-to-Use Primary Packaging Market, 2021-2030: Distribution by Type of Fabrication Material Used
12.3.2.1. Pre-Sterilized/Ready-to-Use Glass Containers Market, 2021-2030
12.3.2.1.1. Pre-Sterilized/Ready-to-Use Glass Vials Market, 2021-2030
12.3.2.1.2. Pre-Sterilized/Ready-to-Use Glass Syringes Market, 2021-2030
12.3.2.1.3. Pre-Sterilized/Ready-to-Use Glass Cartridges Market, 2021-2030
12.3.2.2. Pre-Sterilized/Ready-to-Use Plastic Containers Market, 2021-2030
12.3.2.2.1. Pre-Sterilized/Ready-to-Use Plastic Vials Market, 2021-2030
12.3.2.2.2. Pre-Sterilized/Ready-to-Use Plastic Syringes Market, 2021-2030
12.3.2.2.3. Pre-Sterilized/Ready-to-Use Plastic Cartridges Market, 2021-2030
12.3.3. Pre-Sterilized/Ready-to-Use Primary Packaging Market, 2021-2030: Distribution by Geography
12.3.3.1. Pre-Sterilized/Ready-to-Use Primary Packaging Market in North America, 2021-2030
12.3.3.1.1. Pre-Sterilized/Ready-to-Use Vials Market in North America, 2021-2030
12.3.3.1.2. Pre-Sterilized/Ready-to-Use Syringes Market in North America, 2021-2030
12.3.3.1.3. Pre-Sterilized/Ready-to-Use Cartridges Market in North America, 2021-2030
12.3.3.1.4. Pre-Sterilized/Ready-to-Use Closures Market in North America, 2021-2030
12.3.3.2. Pre-Sterilized/Ready-to-Use Primary Packaging Market in Europe, 2021-2030
12.3.3.2.1. Pre-Sterilized/Ready-to-Use Vials Market in Europe, 2021-2030
12.3.3.2.2. Pre-Sterilized/Ready-to-Use Syringes Market in Europe, 2021-2030
12.3.3.2.3. Pre-Sterilized/Ready-to-Use Cartridges Market in Europe, 2021-2030
12.3.3.2.4. Pre-Sterilized/Ready-to-Use Closures Market in Europe, 2021-2030
12.3.3.3. Pre-Sterilized/Ready-to-Use Primary Packaging Market in Asia-Pacific, 2021-2030
12.3.3.3.1. Pre-Sterilized/Ready-to-Use Vials Market in Asia-Pacific, 2021-2030
12.3.3.3.2. Pre-Sterilized/Ready-to-Use Syringes Market in Asia-Pacific, 2021-2030
12.3.3.3.3. Pre-Sterilized/Ready-to-Use Cartridges Market in Asia-Pacific, 2021-2030
12.3.3.3.4. Pre-Sterilized/Ready-to-Use Closures Market in Asia-Pacific, 2021-2030
12.3.3.4. Pre-Sterilized/Ready-to-Use Primary Packaging Market in Middle East and North Africa, 2021-2030
12.3.3.4.1. Pre-Sterilized/Ready-to-Use Vials Market in Middle East and North Africa, 2021-2030
12.3.3.4.2. Pre-Sterilized/Ready-to-Use Syringes Market in Middle East and North Africa, 2021-2030
12.3.3.4.3. Pre-Sterilized/Ready-to-Use Cartridges Market in Middle East and North Africa, 2021-2030
12.3.3.4.4. Pre-Sterilized/Ready-to-Use Closures Market in Middle East and North Africa, 2021-2030
12.3.3.5. Pre-Sterilized/Ready-to-Use Primary Packaging Market in Latin America, 2021-2030
12.3.3.5.1. Pre-Sterilized/Ready-to-Use Vials Market in Latin America, 2021-2030
12.3.3.5.2. Pre-Sterilized/Ready-to-Use Syringes Market in Latin America, 2021-2030
12.3.3.5.3. Pre-Sterilized/Ready-to-Use Cartridges Market in Latin America, 2021-2030
12.3.3.5.4. Pre-Sterilized/Ready-to-Use Closures Market in Latin America, 2021-2030
12.3.3.6. Pre-Sterilized/Ready-to-Use Primary Packaging Market in Rest of the World, 2021-2030
12.3.3.6.1. Pre-Sterilized/Ready-to-Use Vials Market in Rest of the World, 2021-2030
12.3.3.6.2. Pre-Sterilized/Ready-to-Use Syringes Market in Rest of the World, 2021-2030
12.3.3.6.3. Pre-Sterilized/Ready-to-Use Cartridges Market in Rest of the World, 2021-2030
12.3.3.6.4. Pre-Sterilized/Ready-to-Use Closures Market in Rest of the World, 2021-2030

13. CONCLUSION
14. EXECUTIVE INSIGHTS
14.1. Chapter Overview
14.2. Aseptic Technologies
14.2.1. Company Snapshot
14.2.2. Interview Transcript: Julien Maréchal, Business Development and Technology Director
14.3. BioPhorum Operations Group
14.3.1. Company Snapshot
14.3.2. Interview Transcript: Malcolm Gilmore, Facilitator
14.4. PYRAMID Laboratories
14.4.1. Company Snapshot
14.4.2. Interview Transcript: Konstantin Kazarian, Former Project Manager of Business Development
14.5. Sagar Rubber
14.5.1. Company Snapshot
14.5.2. Interview Transcript: Daxesh Shah, Founder and Managing Director

15. APPENDIX 1: TABULATED DATA16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • ABB
  • Afton Scientific
  • ALK Life Science Solutions
  • Allergy Laboratories
  • American Nurses Foundation
  • American Red Cross
  • AptarGroup
  • ARaymondlife
  • Aseptic Technologies
  • AST
  • Becton Dickinson
  • Berkshire Sterile Manufacturing
  • Bharat Rubber Works
  • Biomedical Advanced Research and Development Authority 
  • BioPharma Solutions
  • Bormioli Pharma
  • Catalent
  • Centor
  • China Lemon Trading
  • Coalition for Epidemic Preparedness Innovations
  • COLANAR
  • Corning
  • COVID-19 Solidarity Response Fund
  • Credence MedSystems
  • Daikyo Seiko
  • Dara Pharmaceutical Packaging
  • Datwyler Group
  • DENSO
  • Disposable-Lab (Acquired by Amatsigroup)
  • DWK Life Sciences
  • EMA Pharmaceuticals
  • Amatsigroup (Acquired by Eurofins CDMO)
  • FANUC America
  • GCL Pharma (Acquired by Bormioli Pharma)
  • Gerresheimer
  • Government of Canada
  • Helapet
  • Hindustan Syringes and Medical Devices
  • Huayi Isotopes Company
  • IMA
  • ISOLAB
  • Jiangsu Hualan New Pharmaceutical Material
  • Kawasaki Heavy Industries
  • Klenzaids Contamination Controls
  • KUKA
  • Marchesini Group
  • MedCision
  • MedicoPack 
  • Merck
  • Microsoft
  • Momentive Technologies
  • Muller + Muller (Acquired by DWK Life Sciences)
  • Nelson Labs
  • Nemera
  • Ningbo Zhengli Pharmaceutical Packaging 
  • Nipro
  • No Kid Hungry 
  • OMRON Industrial Automation
  • Origin Pharma Packaging
  • Ott (Acquired by Datwyler Group)
  • Pall
  • Pfeiffer Vacuum
  • Pfizer
  • Philabundance
  • Prince Sterilization Services
  • Qingdao Huaren Medical Product
  • Radpharm Scientific
  • Retractable Technologies
  • Sagar Rubber
  • Samsung Medical Rubber
  • Sartorius
  • SCHOTT
  • SCHOTT KAISHA
  • Seiko Epson
  • SGD Pharma
  • Sharp
  • SiO2 Materials Science
  • Sonata Rubber
  • Staubli
  • Steriline
  • Sterisets International 
  • Stevanato Group
  • SureCare
  • SVM Automatik
  • Swissfillon
  • Syntegon
  • Tekpak
  • Terumo
  • Toxikon Europe (Acquired by Sterigenics International)
  • Transcoject
  • Triveni Polymers (Acquired by Gerresheimer)
  • Tyndall National Institute
  • Universal Medicap
  • Universal Robots
  • United Pharmacy Partners (UPPI)
  • US Government 
  • Vaccines Manufacturing and Innovation Centre
  • Vanrx Pharmasystems
  • Vetter Pharma
  • VIGHNESH Rubbers
  • Watson-Marlow Fluid Technology Group
  • West Pharmaceutical Services
  • YangZhong Wealth Metal
  • Yaskawa Electric
  • Ypsomed

Methodology

 

 

Loading
LOADING...